ecancerHub - A New Approach to Cancer Communication

eurocancercoms has announced the launch of ecancerHub - a new, open-access, integrated approach to providing the whole cancer community - patients, doctors, researchers and policymakers - with high quality and trustworthy information. Integrating the best of social media technology into one unique platform, ecancerHub enables patients, healthcare professionals and researchers to interact, connect and share. They have the opportunity to discuss, debate, generate new ideas, gather opinions and build knowledge not only within their own groups, but also cross-community.

ecancerHub is the product of the Eurocancercoms project, led by the European Institute of Oncology in Milan, which has been looking at issues and bottlenecks surrounding the communication and dissemination of cancer information across Europe, with the aim of establishing a single, efficient network for cancer communication in Europe.

"We are excited and gratified with the response of the partners in the project, who recognised the need for a communication solution for all those involved in cancer across Europe", says Professor Gordon McVie, Managing Editor of ecancermedicalscience and one of the leaders of the project. "We are particularly pleased with the proposed solution, which we have now launched. ecancerHub fulfils our vision of a 'one-stop-shop' and we strongly urge you to use and help develop it further."

Research conducted as part of the project highlighted the need for a trusted online common platform for healthcare professionals, patients, researchers and policymakers to be able to communicate, network, share and produce knowledge(1). ecancerHub provides a unique solution to fill this gap.

The cancer community now has a unique way of using social media to the benefit and betterment of oncology at their fingertips.

Professor Richard Sullivan of the European Cancer Research Managers Forum and a leader of the project says "We have this excellent platform and now we want the cancer community to get involved, upload content and make this a buzzing hub of ideas and information."

With the help of the community, ecancerHub beta will develop into a fully functioning and thriving platform.

Visit ecancerHub to join the discussion, search for useful tools and databases, upload and view videos, create and read blog posts and more.

1. R. Warden, The Internet and science communication: blurring the boundaries, ecancermedicalscience, 4, 2010, DOI: 10.3332/ecancer.2010.203

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...